Charles River Laboratories International, Inc.
CRL
$138.79
-$2.57-1.82%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.02B | 4.05B | 4.06B | 4.08B | 4.11B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.02B | 4.05B | 4.06B | 4.08B | 4.11B |
| Cost of Revenue | 2.63B | 2.65B | 2.62B | 2.63B | 2.63B |
| Gross Profit | 1.39B | 1.40B | 1.44B | 1.45B | 1.48B |
| SG&A Expenses | 722.92M | 723.82M | 723.71M | 710.68M | 743.46M |
| Depreciation & Amortization | 135.66M | 138.47M | 131.27M | 133.10M | 135.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.49B | 3.51B | 3.47B | 3.47B | 3.51B |
| Operating Income | 530.79M | 539.76M | 587.54M | 607.05M | 606.09M |
| Income Before Tax | 30.08M | 93.11M | 518.61M | 540.24M | 549.25M |
| Income Tax Expenses | 53.39M | 67.82M | 90.62M | 94.53M | 98.36M |
| Earnings from Continuing Operations | -23.31 | 25.29 | 427.99 | 445.72 | 450.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.98M | -8.72M | -9.84M | -9.83M | -12.08M |
| Net Income | -25.29M | 16.57M | 418.15M | 435.88M | 438.82M |
| EBIT | 530.79M | 539.76M | 587.54M | 607.05M | 606.09M |
| EBITDA | 882.64M | 892.10M | 927.69M | 937.88M | 928.50M |
| EPS Basic | -0.63 | 0.17 | 8.04 | 8.40 | 8.55 |
| Normalized Basic EPS | 4.72 | 4.83 | 5.69 | 5.78 | 5.68 |
| EPS Diluted | -0.65 | 0.15 | 7.99 | 8.35 | 8.50 |
| Normalized Diluted EPS | 4.70 | 4.80 | 5.66 | 5.74 | 5.65 |
| Average Basic Shares Outstanding | 204.76M | 205.52M | 205.69M | 205.58M | 205.25M |
| Average Diluted Shares Outstanding | 205.42M | 206.41M | 206.90M | 206.92M | 206.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |